( MENAFN - GetNews) DelveInsight's, “Glioblastoma Pipeline Insight, 2024,” report provides comprehensive insights about 195+ companies and 210+ pipeline drugs in Glioblastoma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type.
It further highlights the inactive pipeline products in this space. Key Takeaways from the Glioblastoma Pipeline Report Explore our comprehensive Glioblastoma Pipeline Report to stay informed about the latest advancements. Download copy now @ Glioblastoma Pipeline Outlook Glioblastoma Overview Glioblastoma, often referred to as glioblastoma multiforme (GBM), is an aggressive and malignant form of brain tumor that originates in the glial cells of the brain.
It is categorized as a grade IV astrocytoma, characterized by its rapid growth and invasive nature within the brain tissue. Glioblastomas are notorious for their resistance to treatment and high recurrence rates despite aggressive therapies such as surgery, radiation, and chemotherapy. Symptoms vary depending on the tumor's location but commonly include headaches, nausea, cognitive impairment, and neurological deficits.
The prognosis for glioblastoma remains challenging, with most patients facing a median survival of approximately 12 to 15 months after diagnosis, highlighting the urgent need for continued research into more effectiv.
